Elvitegravir

• CAT Number: A000301
• CAS Number: 697761-98-1
• Molecular Formula: C₂₃H₂₃ClFNO₅
• Molecular Weight: 447.88
• Purity: ≥95%
• Synonyms: GS-9137; JTK-303; EVG; D06677
• Target: Anti-infection
• IUPAC Name: 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
• InChI: InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
• InChIKey: JUZYLCPPVHEVSV-LJQANCHMSA-N
• SMILES: CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O

Elvitegravir（Cat No.:A000301）is an antiretroviral drug used in combination therapies to treat HIV-1 infection. It is an integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, which is crucial for viral DNA integration into the host genome. By inhibiting this process, elvitegravir prevents the replication of the virus within human cells. It is often co-administered with a pharmacokinetic booster like cobicistat to enhance its efficacy. Elvitegravir is a key component in fixed-dose combination regimens for HIV treatment, offering a potent option for managing the infection and maintaining viral suppression.